Ticker League

EBITDA Margin for Alnylam Pharmaceuticals (ALNY)

As of · Reported

Metric

TTM

14.3%

YoY change

+22.96pp

Trough year (2018)

-1006.9%

Peak year (2025)

15.0%

EBITDA Margin history chart for Alnylam Pharmaceuticals (ALNY) from 2004 to 2025

Latest: 15.0%

EBITDA Margin change chart for Alnylam Pharmaceuticals (ALNY) from 2004 to 2025

Latest: +22.96pp

EBITDA Margin history table for Alnylam Pharmaceuticals (ALNY) from 2004 to 2025

  • 202515.0%+22.96pp
  • 2024-8.0%+6.17pp
  • 2023-14.1%+75.19pp
  • 2022-89.3%-10.96pp
  • 2021-78.4%+71.05pp
  • 2020-149.4%+245.63pp
  • 2019-395.0%+611.86pp
  • 2018-1006.9%-463.92pp
  • 2017-543.0%+325.28pp
  • 2016-868.2%-194.33pp
  • 2015-673.9%-333.16pp
  • 2014-340.8%-165.39pp
  • 2013-175.4%-97.86pp
  • 2012-77.5%-17.46pp
  • 2011-60.0%-22.00pp
  • 2010-38.0%+2.75pp
  • 2009-40.8%-21.11pp
  • 2008-19.7%+127.78pp
  • 2007-147.5%-14.95pp
  • 2006-132.5%+546.74pp
  • 2005-679.3%+11.47pp
  • 2004-690.7%—

EBITDA Margin values are taken from Alnylam Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA Margin at Alnylam Pharmaceuticals (ALNY)

According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported EBITDA margin is 14.3%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

The 2025 reading of Alnylam Pharmaceuticals (ALNY) EBITDA margin is 15.00% – expanded 23.0 percentage points year-over-year.

The highest annual EBITDA margin of 15.00% was reported in 2025. The lowest in the available history was -1006.89% in 2018.

Alnylam Pharmaceuticals EBITDA Margin by Year

Alnylam Pharmaceuticals EBITDA Margin 2025: 15.0%

In 2025, Alnylam Pharmaceuticals reported EBITDA margin of 15.00%, expanded 23.0 percentage points from 2024. This figure represents the highest annual value in the available history.

Alnylam Pharmaceuticals EBITDA Margin 2024: -8.0%

Alnylam Pharmaceuticals EBITDA margin in 2024 was -7.95%, expanded 6.2 percentage points from 2023.

Alnylam Pharmaceuticals EBITDA Margin 2023: -14.1%

2023's EBITDA margin for Alnylam Pharmaceuticals came in at -14.12%, expanded 75.2 percentage points from 2022.

Alnylam Pharmaceuticals EBITDA Margin 2022: -89.3%

Alnylam Pharmaceuticals posted EBITDA margin of -89.31% in 2022, contracted 11.0 percentage points from 2021.

Alnylam Pharmaceuticals EBITDA Margin 2021: -78.4%

Alnylam Pharmaceuticals EBITDA margin in 2021 was -78.36%.

See more financial history for Alnylam Pharmaceuticals (ALNY).

Sector peers by EBITDA Margin

Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest EBITDA margin

Frequently asked questions

Alnylam Pharmaceuticals (ALNY) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Capital Return

No dividends or stock splits on record for this company.